Prestige Consumer Healthcare stock falls as analysts stay cautious

Prestige Consumer Healthcare Inc stock (ISIN US74116D1037) traded under pressure in recent sessions, with the New York Stock Exchange listing opening at USD 44.92 on September 18, 2026 and remaining close to its twelve month low of USD 42.62 as investors reassess the outlook for the consumer health products group.

Analyst consensus signals limited upside

According to MarketBeat on September 20, 2026, Prestige Consumer Healthcare stock currently carries a consensus Hold rating from six brokerages, with one sell recommendation, three hold ratings and two buy ratings.

The same analyst overview from MarketBeat reports an average 12 month price target of USD 70.75 for PBH, implying that, relative to the USD 44.92 opening price on September 18, 2026, analysts see potential upside of about 57.6 percent over the coming year if the company delivers on expectations.

In terms of ownership structure, MarketBeat highlights that institutional investors hold about 99.95 percent of Prestige Consumer Healthcare shares, with large asset managers such as Capital Research Global Investors owning more than 560,000 shares worth roughly USD 34.6 million after increasing their positions in recent periods.

Recent quarterly figures beat expectations

The analyst summary from MarketBeat notes that Prestige Consumer Healthcare exceeded expectations in its most recent reported quarter, delivering earnings per share of USD 0.98 compared with a consensus estimate of USD 0.89.

According to the same overview from MarketBeat, Prestige Consumer Healthcare generated quarterly revenue of USD 265.71 million in the same period, representing year over year growth of 6.5 percent as the company benefited from steady demand for its over the counter healthcare brands.

This combination of mid single digit revenue growth and an earnings beat offers fundamental support to the equity story, even if the Hold consensus indicates that many analysts see the stock as fairly valued relative to its risks, leverage and growth profile rather than a clear outperform candidate.

Valuation metrics and trading range

On the valuation side, the September 20, 2026 performance snapshot from MarketBeat shows that Prestige Consumer Healthcare has a market capitalization of about USD 2.13 billion at the recent price level, corresponding to a price to earnings ratio of 12.58 and a price to earnings growth ratio of 1.41.

The same data from MarketBeat indicate that the company operates with a quick ratio of 1.99 and a current ratio of 3.23, while its debt to equity ratio stands at 1.06, underlining a balance sheet that blends solid liquidity with a moderate level of leverage often seen in consumer products roll up strategies.

From a trading perspective, MarketBeat reports that Prestige Consumer Healthcare shares have a twelve month low of USD 42.62 and a twelve month high of USD 71.07, placing the USD 44.92 opening price on September 18, 2026 only about 5.4 percent above the low and roughly 36.8 percent below the high.

In addition, the same snapshot shows that the stock’s 50 day moving average price is USD 50.56 and its 200 day moving average is USD 52.68, meaning that the current trading level sits clearly below both medium term and long term trend indicators, a configuration that often reflects investor caution or a reassessment of growth expectations.

Stock price and trading metrics

Prestige Consumer Healthcare stock opened at USD 44.92 on the New York Stock Exchange on September 18, 2026, according to the performance section of the analyst overview on MarketBeat, and traded with a beta of 0.33, signaling comparatively low volatility versus the broader equity market.

At the market capitalization of USD 2.13 billion reported by MarketBeat as of September 18, 2026, the shares trade at valuation multiples that are noticeably below many faster growing healthcare names, while the relatively tight 12 month range between USD 42.62 and USD 71.07 suggests that the pricing debate centers more on incremental growth and deleveraging than on binary balance sheet risks.

More news and analyses on Prestige Consumer Healthcare stock